Home » Stocks » Seattle Genetics

Seattle Genetics, Inc. (SGEN)

Stock Price: $160.45 USD -1.35 (-0.83%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $159.40 -1.05 (-0.65%) Aug 7, 7:59 PM

Stock Price Chart

Key Info

Market Cap 27.92B
Revenue (ttm) 1.02B
Net Income (ttm) -255.68M
Shares Out 174.00M
EPS (ttm) -1.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $160.45
Previous Close $161.80
Change ($) -1.35
Change (%) -0.83%
Day's Open 161.52
Day's Range 158.74 - 162.75
Day's Volume 727,652
52-Week Range 65.44 - 187.99

More Stats

Market Cap 27.92B
Enterprise Value 27.09B
Earnings Date (est) Oct 22, 2020
Ex-Dividend Date n/a
Shares Outstanding 174.00M
Float 125.19M
EPS (basic) -1.48
EPS (diluted) -1.49
FCF / Share -1.80
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.21M
Short Ratio 3.68
Short % of Float 7.32%
Beta 1.41
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 27.49
PB Ratio 15.59
Revenue 1.02B
Operating Income -334.52M
Net Income -255.68M
Free Cash Flow -312.41M
Net Cash 832.01M
Net Cash / Share 4.78
Gross Margin 15.10%
Operating Margin -32.94%
Profit Margin -25.20%
FCF Margin -30.76%
ROA -11.20%
ROE -16.57%
ROIC -18.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (19)

Buy 11
Overweight 0
Hold 7
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

(14.02% upside)
Current: $160.45
Target: 182.94
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth40.02%35.76%15.33%24.15%17.45%6.5%27.73%122.43%-11.81%-
Gross Profit87356642837629925824819791.66107
Operating Income-221-260-196-143-121-77.36-62.86-57.25-144-68.20
Net Income-159-223-126-140-120-76.14-62.52-53.78-152-66.27
Shares Outstanding165158143141129123122118113101
Earnings Per Share-0.96-1.41-0.88-1.00-0.93-0.62-0.51-0.46-1.34-0.66
Operating Cash Flow-164-204-119-96.97-133-60.00-1.1110.88-1246.81
Capital Expenditures-70.75-21.22-70.38-27.84-13.39-17.18-22.15-10.49-11.25-3.55
Free Cash Flow-234-225-189-125-147-77.18-23.260.40-1353.26
Cash & Equivalents811411413589650313374364331282
Total Debt67.61---------
Net Cash / Debt743411413589650313374364331282
Book Value1,8761,274678634686211230226219162
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Seattle Genetics, Inc.
Country United States
Employees 1,605
CEO Clay B. Siegall

Stock Information

Ticker Symbol SGEN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SGEN


Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seattle Genetics, Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and biotechnology and pharmaceutical companies. Seattle Genetics, Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.